Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost

Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.